First Trust NYSE Arca Biotechnology Index Fund is an exchange-traded fund (ETF) that primarily tracks the performance of the NYSE Arca Biotechnology Index. Designed to provide investors exposure to the biotechnology sector, this ETF includes companies involved in the research, development, and manufacture of various therapeutics and medical treatments. Its primary function is to provide liquidity and diversification, allowing investors to gain access to a wide array of biotechnology companies through a single financial instrument. The fund comprises a basket of stocks from prominent biotechnology companies, reflecting the dynamic and innovative nature of this sector. Given the rising demand for advanced medical solutions, this ETF plays a critical role in the financial markets by enabling investors to capitalize on the growth potential within the biotech industry. Furthermore, it actively impacts sectors such as pharmaceuticals, healthcare, and life sciences. By spreading investments across a variety of companies, the fund helps mitigate individual company risk, thus appealing to investors seeking both growth opportunities and sector diversification.
United States
Cathie Wood’s ARKG bought Ionis, Beam, Veracyte and Scribe Therapeutics. Here are the biotech ETFs that also hold her latest bets.
One fund offers broad sector exposure at 0.08% cost; the other concentrates on 30 biotech stocks with higher volatility but stronger recent returns.
XBI's lower fees and 155-stock portfolio contrast sharply with FBT's concentrated 30-holding approach, though FBT has experienced less volatility over the past five years.
FBT delivered 57.7% returns over one year but with nearly double the maximum drawdown. IYH offers lower costs and steadier performance for risk-averse investors.
FBT delivered 48.5% returns over one year but carries a 0.55% expense ratio and experiences greater volatility. XLV offers lower costs, with an 0.08% expense ratio, as well as broader diversification across 60 healthcare stocks.
Most biotech investors treat FBT and IBB as two names for the same trade, but the structural differences buried in their index methodologies have produced shockingly different outcomes depending on where the market's momentum actually lives.
Investors talking about FBT also mention
| # | Name | Attention |
|---|---|---|
| 1 | VanEck Biotech ETFBBH | 0%new |
| 2 | iShares Biotechnology ETFIBB | 0.01%0 |
| 3 | ProShares Ultra Nasdaq BiotechnologyBIB | 0%new |
| 4 | Virtus LifeSci Biotech Clinical Trials ETFBBC | 0%0 |
| 5 | First Trust Dow Jones Internet Index FundFDN | 0%0 |
| 6 | SPDR S&P Biotech ETFXBI | 0.42%+0.08 |
| 7 | ALPS Medical Breakthroughs ETFSBIO | 0%new |
| 8 | Vanguard Health Care ETFVHT | 0.13%+0.13 |
| 9 | Microbot Medical Inc.MBOT | 0%+0 |
| 10 | iShares U.S. Medical Devices ETFIHI | 0%-0.02 |
What share of all ETF conversation is about FBT?
| 1 Day1D | 1 Week1W | 1 Month1M | 1 Year1Y | 50-Day MAclick to plot | 200-Day MAclick to plot | |
|---|---|---|---|---|---|---|
| Attention | 0% 0 | 0% 0 | 0% +0 | 0% +0 |
Of the messages about FBT that take a side, what share is each?
| 1 Day1D | 1 Week1W | 1 Month1M | 1 Year1Y | 50-Day MAclick to plot | 200-Day MAclick to plot | |
|---|---|---|---|---|---|---|
| Bullish | — | — | — | 100% 0 | ||
| Bearish | — | — | — | 0% 0 |
Of the messages about FBT that carry a topic, what share is each?
| 1 Day1D | 1 Week1W | 1 Month1M | 1 Year1Y | 50-Day MAclick to plot | 200-Day MAclick to plot | |
|---|---|---|---|---|---|---|
| Macro | — | — | — | 0% | ||
| Technical Analysis | — | — | — | 100% |
Of the messages about FBT, what share comes from each group?
| 1 Day1D | 1 Week1W | 1 Month1M | 1 Year1Y | 50-Day MAclick to plot | 200-Day MAclick to plot | |
|---|---|---|---|---|---|---|
| Regulars | — | — | 0% | 5.91% | ||
| Newcomers | — | — | 100% | 94.09% |